Hematology - European Medical Journal

Continue

Hematology

Filter
Hematology CP
11 Mins
13 Nov 2020

Is Allogeneic Stem Cell Transplantation a Good Option for Paroxysmal Nocturnal Haemoglobinuria?

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare disease of nonmalignant clonal haematopoietic stem cells with an estimated prevalence of 1–16 cases per million, which may be underestimated because of undiagnosed patients…
EMJ Hematology 8 [Supplement 5] 2020 Feature Image
12 Mins
24 Sep 2020

The Impact of Sickle Cell Disease: Updates in Therapeutics, Treatment, Management, and Future Directions

Although VOC are the hallmark of SCD, a lack of VOC events does not prevent chronic multi-organ damage. Patients with sickle cell anaemia (SCA)…
EMJ Hematology 8 [Supplement 4] 2020 Feature Image
2 Mins
18 Sep 2020

European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukaemia: Implications for Ponatinib

Ponatinib is indicated for the treatment of adults with chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib, are intolerant…
9 Mins
17 Sep 2020

Economic Evaluation of Severe Anaemia

Anaemia is characterised by a decrease in the total amount of red blood cells (RBC) and haemoglobin (Hb) levels, reducing the volume of oxygen transported through the blood…
Doing More for Patients with Immune Thrombocytopenia
9 Mins
30 Jul 2020

Doing More for Patients with Immune Thrombocytopenia: Putting New Recommendations into Practice

The American Society of Hematology (ASH) guidelines and the International Consensus Report (ICR) recommendations were first published in 2010 and 2011…
hematology 8.1 featured image
10 Mins
30 Jul 2020

Outcomes for Patients with High-Risk Acute Myeloid Leukaemia: Can We Move from Months to Years?

This symposium focussed on the recognition of, and treatment options for, high-risk AML. Prof Cluzeau considered universal or targeted treatment…
AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study
2 Mins
30 Jul 2020

AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukaemia and an IDH1 Mutation

Isocitrate dehydrogenase 1 (IDH1) is a metabolic enzyme which catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate…
Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib
3 Mins
30 Jul 2020

Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib, with the BCL2-Inhibitor Venetoclax +/-Azacitidine in IDH1-Mutated Myeloid Malignancies

Venetoclax is a potent, selective, oral inhibitor of B-cell lymphoma-2. It is approved in the USA in combination with azacitidine, decitabine…